Fig. 2
From: Umbilical cord blood plasma-derived exosomes as a novel therapy to reverse liver fibrosis
UCB-Exo inhibit primary HSC activation and collagen production. Primary HSCs were incubated with PKH-labeled exosomes (20 µg/mL) for 12 h and analyzed by flow cytometry (A) and microscopy (B). Blue: DAPI; Green: PKH-labeled UCB-Exo. Scale bar: 50 µm. HSCs were exposed to different concentrations of UCB-Exo for 24 h and cell proliferation is presented in (C). qRT-PCR analyses of collagen 1α1 expression in treatment with UCB-Exo for 24 h (D). Soluble collagen I content was measured in culture media after 24 h of UCB-Exo treatment (E). Western blotting analysis of MMP-2, MMP-9, MMP-13, TIMP-1, TIMP-2, and TGF-β expression after 72 h of UCB-Exo treatment (F). Quantification of western blot results was performed by calculating the ratio of the value to that of actin. Data are presented as the mean ± SEM. *p < 0.05 and ***p < 0.001